Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone topical - AbbVie/Besins/Viatris

Drug Profile

Testosterone topical - AbbVie/Besins/Viatris

Alternative Names: 1% Testosterone gel (AndroGel) - AbbVie; 1.62% Testosterone gel - Solvay; AndroGel; AndroGel PD; Testogel; Testosterone topical - Abbott

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Besins International; Unimed Pharmaceuticals
  • Developer AbbVie; Besins Healthcare; Solvay
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Growth stimulants; Testosterone congener stimulants; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypogonadism
  • Discontinued Growth disorders

Most Recent Events

  • 23 Oct 2023 Solvay withdraws a phase-II trial in Hypogonadism and Pain in USA prior to enrolment (NCT00398034)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 07 Aug 2018 Solvay Pharmaceuticals completes a phase I trial in Hypogonadism in USA (Topical) (NCT00425568)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top